Evidence map›Paper›PMID 30064428›Full record

ArticleBMC health services research2018

Using value of information methods to determine the optimal sample size for effectiveness trials of alcohol interventions for HIV-infected patients in East Africa.

Lingfeng Li, Jennifer Uyei, Kimberly A Nucifora, Jason Kessler, Elizabeth R Stevens, Kendall Bryant, R Scott Braithwaite

Open access · goldAbstract read
In one paragraph

Article in BMC health services research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.7field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Lingfeng LiDepartment of Population Health, New York University School of Medicine, 227 East 30th Street, Floor 6, New York, NY, 10016, USA.
Jennifer UyeiDepartment of Population Health, New York University School of Medicine, 227 East 30th Street, Floor 6, New York, NY, 10016, USA.
Kimberly A NuciforaDepartment of Population Health, New York University School of Medicine, 227 East 30th Street, Floor 6, New York, NY, 10016, USA. kimberly.nucifora@nyumc.org.
Jason KesslerDepartment of Population Health, New York University School of Medicine, 227 East 30th Street, Floor 6, New York, NY, 10016, USA.
Elizabeth R StevensDepartment of Population Health, New York University School of Medicine, 227 East 30th Street, Floor 6, New York, NY, 10016, USA.
Kendall BryantNational Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, MD, USA.
R Scott BraithwaiteDepartment of Population Health, New York University School of Medicine, 227 East 30th Street, Floor 6, New York, NY, 10016, USA.
New York University · USNational Institutes of Health · US

Funding

The Operations Research Collaboration for Alcohol Abuse and AIDS: ORCAAAU24AA022007 · NIAAA · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI BRAITHWAITE, RONALD SCOTT · 2012 to 2016
$3.4M
NIAAA NIH HHS 5U24AA022007-03NIAAA NIH HHS U24 AA022007
6 · The paper itself

Abstract

backgroundUnhealthy alcohol consumption exacerbates the HIV epidemic in East Africa. Potential benefits of new trials that test the effectiveness of alcohol interventions could not be evaluated by traditional sampling methods. Given the competition for health care resources in East Africa, this study aims to determine the optimal sample size given the opportunity cost of potentially re-allocating trial funds towards cost-effective alcohol treatments.

methodsWe used value of information methods to determine the optimal sample size by maximizing the expected net benefit of sampling for a hypothetical 2-arm intervention vs. control randomized trial, across ranges of policymaker's willingness-to-pay for the health benefit of an intervention. Probability distributions describing the relative likelihood of alternative trial results were imputed based on prior studies. In the base case, policymaker's willingness-to-pay was based on a simultaneously resource-constrained priority (routine HIV virological testing). Sensitivity analysis was performed for various willingness-to-pay thresholds and intervention durations.

resultsA new effectiveness trial accounting for the benefit of more precise decision-making on alcohol intervention implementation would benefit East Africa $67,000 with the optimal sample size of 100 persons per arm under the base case willingness-to-pay threshold and intervention duration of 20 years. At both a conservative willingness-to-pay of 1 x GDP/capita and a high willingness-to-pay of 3 x GDP/capita for an additional health gain added by an alcohol intervention, a new trial was not recommended due to limited decision uncertainty. When intervention duration was 10 or 5 years, there was no return on investment across suggested willingness-to-pay thresholds.

conclusionsValue of information methods could be used as an alternative approach to assist the efficient design of alcohol trials. If reducing unhealthy alcohol use is a long-term goal for HIV programs in East Africa, additional new trials with optimal sample sizes ranging from 100 to 250 persons per arm could save the opportunity cost of implementing less cost-effective alcohol strategies in HIV prevention. Otherwise, conducting a new trial is not recommended.

Indexed as

Africa, EasternAlcohol DrinkingCost-Benefit AnalysisData CollectionHealth Care CostsHIV InfectionsHumansQuality-Adjusted Life YearsRandomized Controlled Trials as TopicSample SizeUncertaintyAlcohol interventionEast AfricaHIVOptimal sample sizeValue of information

Identifiers

PMID30064428
PMCPMC6069863
OpenAlexW2886114068

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.